Fatty liver breakthrough? scientists target gene switches
NCT ID NCT06332677
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how certain gene regulators, called SUV420H1/2, affect fatty liver disease (NAFLD). Researchers will analyze data from 260 people and use lab models to see if blocking these genes could reduce liver fat and damage. The goal is to find a new way to treat this common liver condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward a new treatment for fatty liver disease by targeting specific genes.
- What could go wrong
- This is an early-stage observational and lab study, not a clinical treatment trial. Results may not lead to a usable therapy for years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica
RECRUITINGMilan, 20122, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Could a common b vitamin tame fatty liver?
- Can a sugar test reveal how fatty liver begins in obese adolescents?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- Fatty liver disease: a new biobank aims to unlock the secrets of a silent epidemic
- Calorie cutting may reverse a key step toward diabetes